# IND.227 (NCT02784171)

> Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

No report yet. It can be ordered.

- Indication: untreated advanced pleural mesothelioma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02784171
- Phase: PHASE2, PHASE3
- Status: COMPLETED
- Sponsor: Canadian Cancer Trials Group
- Conditions: Mesothelioma
- Interventions: Cisplatin; Pemetrexed; Pembrolizumab
- Enrollment: 520
- Primary outcome: Phase II: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression
- Primary outcome: Phase III: Overall Survival Defined as Time From Randomization to the Date of Death From Any Cause

## Indexed commentary on IND.227 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 31 posts on X
- 9 podcast episodes
- 3 YouTube videos

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ind-227-nct02784171

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02784171", "email": "<work email>"}; the inbox owner confirms by the emailed link.